Understanding dry eye syndrome

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

It was my great pleasure to have had the opportunity to give the conference address in addition to being honored by the Professor Dohlman Award. I am proud of the progress in the understanding of dry eye that has been made over the past couple of decades. However, the clinical application of the knowledge that has accumulated lies in the future. Thus far no effective medication has ever been developed for the treatment of severe dry eye. Cyclosoporine may become the first eyedrops to be used, and a series of new drugs containing androgens, immunomodulators, secretagogues, P2Y2 receptor agonists, and others may follow. I believe that medication for the treatment of dry eye will be developed in the not to distant future, and I hope that at the 4th conference in a few years time, we will be able to share these new treatments for the management of dry eye patients.

Original languageEnglish
Pages (from-to)3-16
Number of pages14
JournalAdvances in Experimental Medicine and Biology
Volume506 A
Publication statusPublished - 2002

Fingerprint

Purinergic P2Y2 Receptors
Dry Eye Syndromes
Ophthalmic Solutions
Immunologic Factors
Androgens
Pharmaceutical Preparations
Pleasure
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Understanding dry eye syndrome. / Tsubota, Kazuo.

In: Advances in Experimental Medicine and Biology, Vol. 506 A, 2002, p. 3-16.

Research output: Contribution to journalArticle

@article{bfee57d5878c48278bd9fe2a91d52da4,
title = "Understanding dry eye syndrome",
abstract = "It was my great pleasure to have had the opportunity to give the conference address in addition to being honored by the Professor Dohlman Award. I am proud of the progress in the understanding of dry eye that has been made over the past couple of decades. However, the clinical application of the knowledge that has accumulated lies in the future. Thus far no effective medication has ever been developed for the treatment of severe dry eye. Cyclosoporine may become the first eyedrops to be used, and a series of new drugs containing androgens, immunomodulators, secretagogues, P2Y2 receptor agonists, and others may follow. I believe that medication for the treatment of dry eye will be developed in the not to distant future, and I hope that at the 4th conference in a few years time, we will be able to share these new treatments for the management of dry eye patients.",
author = "Kazuo Tsubota",
year = "2002",
language = "English",
volume = "506 A",
pages = "3--16",
journal = "Advances in Experimental Medicine and Biology",
issn = "0065-2598",
publisher = "Springer New York",

}

TY - JOUR

T1 - Understanding dry eye syndrome

AU - Tsubota, Kazuo

PY - 2002

Y1 - 2002

N2 - It was my great pleasure to have had the opportunity to give the conference address in addition to being honored by the Professor Dohlman Award. I am proud of the progress in the understanding of dry eye that has been made over the past couple of decades. However, the clinical application of the knowledge that has accumulated lies in the future. Thus far no effective medication has ever been developed for the treatment of severe dry eye. Cyclosoporine may become the first eyedrops to be used, and a series of new drugs containing androgens, immunomodulators, secretagogues, P2Y2 receptor agonists, and others may follow. I believe that medication for the treatment of dry eye will be developed in the not to distant future, and I hope that at the 4th conference in a few years time, we will be able to share these new treatments for the management of dry eye patients.

AB - It was my great pleasure to have had the opportunity to give the conference address in addition to being honored by the Professor Dohlman Award. I am proud of the progress in the understanding of dry eye that has been made over the past couple of decades. However, the clinical application of the knowledge that has accumulated lies in the future. Thus far no effective medication has ever been developed for the treatment of severe dry eye. Cyclosoporine may become the first eyedrops to be used, and a series of new drugs containing androgens, immunomodulators, secretagogues, P2Y2 receptor agonists, and others may follow. I believe that medication for the treatment of dry eye will be developed in the not to distant future, and I hope that at the 4th conference in a few years time, we will be able to share these new treatments for the management of dry eye patients.

UR - http://www.scopus.com/inward/record.url?scp=0036941026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036941026&partnerID=8YFLogxK

M3 - Article

VL - 506 A

SP - 3

EP - 16

JO - Advances in Experimental Medicine and Biology

JF - Advances in Experimental Medicine and Biology

SN - 0065-2598

ER -